CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

761306Orig1s000

PROPRIETARY NAME REVIEW(S)

SUFFIX REVIEW FOR NONPROPRIETARY NAME

Division of Medication Error Prevention and Analysis 1 (DMEPA 1)

Office of Medication Error Prevention and Risk Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	7/11/2024
Responsible OND Division:	Division of Dermatology and Dentistry (DDD)
Application Type and Number:	BLA 761306
Product Name and Strength:	Ebglyss (lebrikizumab-lbkz) injection 250 mg/2 mL (125 mg/mL)
Product Type:	Combination Product (Biologic-Device)
Applicant/Sponsor Name:	Eli Lilly and Company (Lilly)
Nexus NPNS ID #:	2024-242
DMEPA 2 Biologics Suffix Specialist:	Carlos M Mena-Grillasca, BS Pharm
DMEPA 1 Director:	Mishale Mistry, PharmD, MPH

1 PURPOSE OF REVIEW

This review is to reassess the proposed suffix, -lbkz, for BLA 761306, which was found conditionally acceptable on April 24, 2023[a], for inclusion in the nonproprietary name and communicates our recommendation for the nonproprietary name for BLA 761306.

1.1 Regulatory History

FDA found the proposed four-letter suffix, -lbkz, conditionally acceptable for BLA 761306 on April 24, 2023[a]. However, BLA 761306 received a Complete Response (CR) letter on September 28, 2023[b]. Thus, Lilly submitted a Class 2 Resubmission on March 14, 2024.

2 ASSESSMENT OF THE NONPROPRIETARY NAME

We reassessed the previously proposed four-letter suffix, -lbkz, using the principles described in the applicable guidance[c].

We note that the proposed suffix may connote the core name 'lebrikizumab'. However, we do not object to suffixes that connote their own core name.

We determined that the FDA-generated suffix -lbkz, is not too similar to any other products' suffix designation, does not look similar to the names of other currently marketed products, that the suffix is devoid of meaning, does not include any abbreviations that could be misinterpreted, and does not make any misrepresentations with respect to safety or efficacy of this product.

---

[a] Mena-Grillasca, C. Nonproprietary Name Suffix Review for lebrikizumab-lbkz (BLA 761306). Silver Spring (MD): FDA, CDER, OSE, DMEPA 1 (US); 2023 Apr 24. Nexus No.: 2022-98 and 2022-135.

[b] Donohue, K.M. Complete Response (BLA 761306). Silver Spring (MD): FDA, CDER, OND, DDD (US); 2023 Sep 28.

[c] Guidance for Industry: Nonproprietary Naming of Biological Products. 2017. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf

3 COMMUNICATION OF DMEPA 1 ANALYSIS

These findings were shared with OPDP. On June 20, 2024, OPDP did not identify any concerns that would render this suffix unacceptable. DMEPA 1 also communicated our findings to the Division of Dermatology and Dentistry (DDD) on July 11, 2024.

4 CONCLUSION

We find the suffix -lbkz acceptable and recommend the nonproprietary name lebrikizumab-lbkz be used throughout the draft labels and labeling.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CARLOS M MENA-GRILLASCA
07/11/2024 12:08:18 PM

MISHALE P MISTRY
07/12/2024 12:05:09 PM

PROPRIETARY NAME REVIEW

Division of Medication Error Prevention and Analysis 1 (DMEPA 1)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

Date of This Review:	June 11, 2024
Application Type and Number:	BLA 761306
Product Name, Dosage Form, and Strength:	Ebglyss (lebrikizumab-lbkz) injection, 250 mg/2 mL (125 mg/mL)
Product Type:	Combination Product (Biologic-Device)
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Eli Lilly and Company (Eli Lilly)
PNR ID #:	2024-1044725804
DMEPA 1 Safety Evaluator:	Madhuri R. Patel, PharmD
DMEPA 1 Team Leader:	Yevgeniya Kogan, PharmD, BCSCP
DMEPA 1 Associate Director for Nomenclature and Labeling:	Idalia E. Rychlik, PharmD

Table of Contents

1 INTRODUCTION

This review evaluates the proposed proprietary name, Ebglyss, from a safety and misbranding perspective. The sources and methods used to evaluate the proposed proprietary name are outlined in the Reference section and Appendix A, respectively. Eli Lilly submitted a name study, conducted by Eli Lilly[a], for this proposed proprietary name.

1.1 REGULATORY HISTORY

Eli Lilly previously submitted the proposed proprietary name, [redacted] (b) (4) *** under IND 119866 on June 17, 2021 but was later withdrawn on September 23, 2021.

Subsequently, Eli Lilly submitted the proposed proprietary name, Ebglyss*** under IND 119866 on October 1, 2021, and we found the name conditionally acceptable on March 22, 2022.[b]

Thereafter, Eli Lilly submitted the proposed proprietary name, Ebglyss***, under BLA 761306 on September 28, 2022, and we found the name conditionally acceptable on December 6, 2022.[c] However, BLA 761306 received a Complete Response (CR) on September 28, 2023.

Thus, Eli Lilly submitted the proposed proprietary name, Ebglyss, for review on March 14, 2024 under BLA 761306.

1.2 PRODUCT INFORMATION

The following product information is provided in the proprietary name submission received on March 14, 2024[d].

Table 1. Relevant Product Information for Ebglyss	
Intended pronunciation:	EHB-glihs
Nonproprietary name:	lebrikizumab-lbkz
Indication:	treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Can be used with or without topical corticosteroids
Dosage Form:	injection

[a] Request for Proprietary Name Review. Indianapolis (IN): Eli Lilly; 2024 MAR 14. Available from: \\CDSESUB1\EVSPROD\bla761306\0060\m1\us\m1-18-proprietary-names.pdf.

[b] Patel, M. Proprietary Name Review for Ebglyss*** (IND 119866). Silver Spring (MD): FDA, CDER, OSE, DMEPA 1 (US); 2022 MAR 22. PNR ID No. 2021-1044724212.

[c] Patel, M. Proprietary Name Review for Ebglyss*** (BLA 761306). Silver Spring (MD): FDA, CDER, OSE, DMEPA 1 (US); 2022 DEC 06. PNR ID No. 2022-1044724776.

[d] Proposed Prescribing Information (BLA 761306 Ebglyss). Indianapolis (IN): Eli Lilly and Company; 2024 MAR 14. Available from: \\CDSESUB1\EVSPROD\bla761306\0060\m1\us\annotated.pdf.

<table>
<tr><th colspan="2">Table 1. Relevant Product Information for Ebglyss</th></tr>
<tr><td>Strength:</td><td>250 mg/2 mL (125 mg/mL)</td></tr>
<tr><td>Route of administration:</td><td>subcutaneous</td></tr>
<tr><td>Dose and frequency:</td><td><u>Adults and Pediatric Patients (Age 12 years to less than 18 years and Who Weigh at least 40 kg)</u>
The recommended dosage of EBGLYSS is an initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose is 250 mg every four weeks.</td></tr>
<tr><td>How Supplied:</td><td>sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution, available in a single-dose prefilled pen or a single-dose prefilled syringe with needle shield. Each prefilled pen and prefilled syringe with needle shield is designed to deliver 250 mg of EBGLYSS in 2 mL
<table>
<tr><th></th><th>Pack Size</th><th>NDC</th></tr>
<tr><td>Prefilled Pen</td><td></td><td></td></tr>
<tr><td>250 mg/2 mL single-dose</td><td>Carton of 1</td><td>0002-7772-11</td></tr>
<tr><td>Prefilled syringe with needle shield</td><td></td><td></td></tr>
<tr><td>250 mg/2 mL single-dose</td><td>Carton of 1</td><td>0002-7797-11</td></tr>
</table></td></tr>
<tr><td>Storage:</td><td>Store refrigerated at 2°C to 8°C (36°F to 46°F).
If necessary, EBGLYSS can be stored at room temperature up to 30°C (86°F) for up to 7 days in the original carton.
Dispose of EBGLYSS that has been left at room temperature for longer than 7 days.
Store in the original carton to protect from light until use.
Do not freeze. Do not use EBGLYSS if it has been frozen.
Do not shake.
Do not microwave, run hot water over it, or leave it in direct sunlight.
Not made with natural rubber latex.
Discard the EBGLYSS single-dose prefilled pen or prefilled syringe with needle shield after use in a puncture-resistant container.</td></tr>
</table>

2 DISCUSSION

The following sections provide information obtained and considered in the overall evaluation of the proposed proprietary name, Ebglyss.

2.1 MISBRANDING ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined that Ebglyss would not misbrand the proposed product. The Division of Medication Error Prevention and Analysis 1 (DMEPA 1)

concurred with the findings of OPDP's assessment for Ebglyss. The Division of Dermatology and Dentistry (DDD) concurred with the findings of OPDP's assessment for Ebglyss.

2.2 SAFETY ASSESSMENT

The following aspects were considered in the safety evaluation of the proposed proprietary name, Ebglyss.

2.2.1 UNITED STATES ADOPTED NAMES (USAN) SEARCH

There is no USAN stem present in the proposed proprietary name.[e]

2.2.2 COMPONENTS OF THE PROPOSED PROPRIETARY NAME

Eli Lilly did not provide a derivation or intended meaning for the proposed proprietary name, Ebglyss, in their submission. This proprietary name is comprised of a single word. We note that the proposed proprietary name ends with the letter string '-ss'; 'SS' is the medical abbreviation one half. We previously evaluated the inclusion of this abbreviation within the proposed proprietary name during our previous review[f] and we did not identify concerns with inclusion of this abbreviation from a medication error perspective.

We determined the name Ebglyss is not misleading and beyond the aforementioned abbreviation, we note that Ebglyss does not contain any additional components (i.e. a modifier, route of administration, dosage form, etc.) that are misleading or can contribute to medication error.

2.2.3 COMMENTS FROM OTHER REVIEW DISCIPLINES AT INITIAL REVIEW

On June 11, 2024, the Division of Dermatology and Dentistry (DDD) did not forward any comments or concerns relating to Ebglyss at the initial phase of the review.

2.2.4 FDA PRESCRIPTION SIMULATION STUDIES

Sixty-five (n=65) practitioners participated in DMEPA's prescription simulation studies for Ebglyss. The responses did not overlap with any currently marketed products nor did the responses sound or look similar to any currently marketed products or any products in the pipeline. Appendix B contains the results from the prescription simulation studies.

2.2.5 PHONETIC AND ORTHOGRAPHIC COMPUTER ANALYSIS (POCA) SEARCH RESULTS

Our POCA search[g] identified 16 names with a combined score of ≥55% or an individual orthographic or phonetic score of ≥70%. We had identified and evaluated all of the names in our previous proprietary name review. We re-evaluated the previously identified names of

---

[e] USAN stem search conducted on May 23, 2024.

[f] Patel, M. Proprietary Name Review for Ebglyss*** (IND 119866). Silver Spring (MD): FDA, CDER, OSE, DMEPA 1 (US); 2022 MAR 22. PNR ID No. 2021-1044724212.

[g] POCA search conducted on May 23, 2024 in version 5.9.

concern considering any lessons learned from recent post-marketing experience, which may have altered our previous conclusion regarding the acceptability of the name. We also evaluated previously identified names taking into account (b) (4) the frequency of maintenance dosing (b) (4) 250 mg every 4 weeks. Our evaluation has not altered our previous conclusion regarding the acceptability of the proposed proprietary name, Ebglyss.

2.2.6 NAMES RETRIEVED FOR REVIEW ORGANIZED BY NAME PAIR SIMILARITY

Table 2 provides the number of names retrieved from the Eli Lilly name study that were not evaluated in our previous proprietary name review. These name pairs are organized as highly similar, moderately similar, or low similarity for further evaluation.

Table 2. Names Retrieved for Review Organized by Name Pair Similarity	
Similarity Category	Number of Names
Highly similar name pair: combined match percentage score ≥70%	0
Moderately similar name pair: combined match percentage score ≥55% to ≤ 69%	0
Low similarity name pair: combined match percentage score ≤54%	1

2.2.7 SAFETY ANALYSIS OF NAMES WITH POTENTIAL ORTHOGRAPHIC, SPELLING, AND PHONETIC SIMILARITIES

Our analysis of the one name contained in Table 2 determined none of the names will pose a risk for confusion with Ebglyss as described in Appendices C through H.

2.2.8 COMMUNICATION OF DMEPA'S DETERMINATION

On June 11, 2024, DMEPA 1 communicated our determination to the Division of Dermatology and Dentistry (DDD).

3 CONCLUSION

The proposed proprietary name, Ebglyss, is conditionally acceptable.

If you have any questions or need clarifications, please contact Wana Manitpisitkul, OSE project manager, at (240) 402-4156.

3.1 COMMENTS TO ELI LILLY AND COMPANY

We have completed our review of the proposed proprietary name, Ebglyss, and have concluded that this proprietary name is conditionally acceptable.

If any of the proposed product characteristics as stated in your submission, received on March 14, 2024, are altered prior to approval of the marketing application, the proprietary name must be resubmitted for review.

APPEARS THIS WAY ON ORIGINAL

4 REFERENCES

1. United States Adopted Names (USAN) Stems

USAN Stems List contains all the recognized USAN stems, available at https://www.ama-assn.org/about/united-states-adopted-names/united-states-adopted-names-approved-stems.

2. Phonetic and Orthographic Computer Analysis (POCA)

POCA is a system that FDA designed. As part of the name similarity assessment, POCA is used to evaluate proposed names via a phonetic and orthographic algorithm. The proposed proprietary name is converted into its phonemic representation before it runs through the phonetic algorithm. Likewise, an orthographic algorithm exists that operates in a similar fashion. POCA is publicly accessible.

Drugs@FDA

Drugs@FDA is an FDA Web site that contains most of the drug products approved in the United States since 1939. The majority of labels, approval letters, reviews, and other information are available for drug products approved from 1998 to the present. Drugs@FDA contains official information about FDA-approved brand name and generic drugs; therapeutic biological products, prescription and over-the-counter human drugs; and discontinued drugs (see Drugs@FDA Glossary of Terms, available at https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-glossary-terms).

RxNorm

RxNorm contains the names of prescription and many OTC drugs available in the United States. RxNorm includes generic and branded:

- Clinical drugs – pharmaceutical products given to (or taken by) a patient with therapeutic or diagnostic intent
- Drug packs – packs that contain multiple drugs, or drugs designed to be administered in a specified sequence

Radiopharmaceuticals, contrast media, food, dietary supplements, and medical devices, such as bandages and crutches, are all out of scope for RxNorm (http://www.nlm.nih.gov/research/umls/rxnorm/overview.html).

Purple Book

The Purple Book is an online database that contains information about biological products, including biosimilar and interchangeable biological products, licensed (approved) by the FDA under the Public Health Service (PHS) Act. See Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, available at https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or.

Division of Medication Errors Prevention and Analysis pending proprietary name requests

This is a list of proposed and pending names that is generated by the Division of Medication Error Prevention and Analysis.

5 APPENDICES

APPENDIX A. FDA'S PROPRIETARY NAME RISK ASSESSMENT EVALUATES PROPOSED PROPRIETARY NAMES FOR MISBRANDING AND SAFETY CONCERNS

1. Misbranding Assessment: For prescription drug products, the Office of Prescription Drug Promotion (OPDP) assesses the name for misbranding concerns. For over-the-counter (OTC) drug products, the misbranding assessment of the proposed name is conducted by the Office of Non-Prescription Drugs (ONPD). OPDP or ONPD evaluates proposed proprietary names to determine if the name is false or misleading, such as by making misrepresentations with respect to safety or efficacy. For example, a fanciful proprietary name may misbrand a product by suggesting that it has some unique effectiveness or composition when it does not (21 CFR 201.10(c)(3)). OPDP or ONPD provides their opinion to DMEPA for consideration in the overall acceptability of the proposed proprietary name.

2. Safety Assessment: The safety assessment is conducted by DMEPA, and includes the following:

    a. Preliminary Assessment: We consider inclusion of USAN stems or other characteristics that when incorporated into a proprietary name may cause or contribute to medication errors (i.e., dosing interval, dosage form/route of administration, medical or product name abbreviations, names that include or suggest the composition of the drug product, etc.) See prescreening checklist below in Table 3*. DMEPA defines a medication error as any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer.[h]

*Table 3. Prescreening Checklist for Proposed Proprietary Name Answer the questions in the checklist below. Affirmative answers to any of these questions indicate a potential area of concern that should be carefully evaluated as described in this guidance.	
Y/N	Is the proposed name obviously similar in spelling and pronunciation to other names?
	Proprietary names should not be similar in spelling or pronunciation to proprietary names, established names, or ingredients of other products.
Y/N	Are there inert or inactive ingredients referenced in the proprietary name?
	Proprietary names should not incorporate any reference to an inert or inactive ingredient in a way that might create an impression that the ingredient's value is greater than its true functional role in the formulation (21 CFR 201.10(c)(4)).
Y/N	Does the proprietary name include combinations of active ingredients?
	Proprietary names of fixed combination drug products should not include or suggest the name of one or more, but not all, of its active ingredients (see 21 CFR 201.6(b)).
Y/N	Is there a United States Adopted Name (USAN) stem in the proprietary name?
	Proprietary names should not incorporate a USAN stem in the position that USAN designates for the stem.

[h] National Coordinating Council for Medication Error Reporting and Prevention. https://www.nccmerp.org/about-medication-errors. Last accessed 10/05/2020.

*Table 3. Prescreening Checklist for Proposed Proprietary Name Answer the questions in the checklist below. Affirmative answers to any of these questions indicate a potential area of concern that should be carefully evaluated as described in this guidance.	
Y/N	Is this proprietary name used for another product that does not share at least one common active ingredient?
	Drug products that do not contain at least one common active ingredient should not use the same (root) proprietary name.
Y/N	Is this a proprietary name of a discontinued product?
	Proprietary names should not use the proprietary name of a discontinued product if that discontinued drug product does not contain the same active ingredients.

b. Phonetic and Orthographic Computer Analysis (POCA): Following the preliminary screening of the proposed proprietary name, DMEPA staff evaluates the proposed name against potentially similar names. In order to identify names with potential similarity to the proposed proprietary name, DMEPA enters the proposed proprietary name in POCA and queries the name against the following drug reference databases, Drugs@FDA, Cerner RxNorm, Purple Book, and names in the review pipeline using a 55% threshold in POCA. DMEPA reviews the combined orthographic and phonetic matches and group the names into one of the following three categories:

- Highly similar pair: combined match percentage score ≥70%.
- Moderately similar pair: combined match percentage score ≥55% to ≤ 69%.
- Low similarity: combined match percentage score ≤54%.

Using the criteria outlined in the check list (Table 4-6) that corresponds to each of the three categories (highly similar pair, moderately similar pair, and low similarity), DMEPA evaluates the name pairs to determine the acceptability or non-acceptability of a proposed proprietary name. The intent of these checklists is to increase the transparency and predictability of the safety determination of whether a proposed name is vulnerable to confusion from a look-alike or sound-alike perspective. Each bullet below corresponds to the name similarity category cross-references the respective table that addresses criteria that DMEPA uses to determine whether a name presents a safety concern from a look-alike or sound-alike perspective.

- For highly similar names, differences in product characteristics often cannot mitigate the risk of a medication error, including product differences such as strength and dose. Thus, proposed proprietary names that have a combined score of ≥ 70 percent are at risk for a look-alike sound-alike confusion which is an area of concern (See Table 4).
- Moderately similar names are further evaluated to identify the presence of attributes that are known to cause name confusion.
    - Name attributes: We note that the beginning of the drug name plays a significant role in contributing to confusion. Additionally, drug name pairs that start with the same first letter and contain a shared letter string of at least 3 letters in both names are major contributing factor in

the confusion of drug names[i]. We evaluate all moderately similar names retrieved from POCA to identify the above attributes. These names are further evaluated to identify overlapping or similar strengths or doses.

- Product attributes: Moderately similar names of products that have overlapping or similar strengths or doses represent an area for concern for FDA. The dose and strength information is often located in close proximity to the drug name itself on prescriptions and medication orders, and the information can be an important factor that either increases or decreases the potential for confusion between similarly named drug pairs. The ability of other product characteristics to mitigate confusion (e.g., route, frequency, dosage form) may be limited when the strength or dose overlaps. DMEPA reviews such names further, to determine whether sufficient differences exist to prevent confusion. (See Table 5).

- Names with low similarity that have no overlap or similarity in strength and dose are generally acceptable (See Table 6) unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

c. FDA Prescription Simulation Studies: DMEPA also conducts prescription simulation studies using FDA health care professionals.

   Four separate studies are conducted within the Centers of the FDA for the proposed proprietary name to determine the degree of confusion of the proposed proprietary name with marketed U.S. drug names (proprietary and established) due to similarity in visual appearance with handwritten prescriptions, verbal pronunciation of the drug name or during computerized provider order entry. The studies employ healthcare professionals (pharmacists, physicians, and nurses), and attempts to simulate the prescription ordering process. The primary Safety Evaluator uses the results to identify vulnerability of the proposed name to be misinterpreted by healthcare practitioners during written, verbal, or electronic prescribing.

   In order to evaluate the potential for misinterpretation of the proposed proprietary name during written, verbal, or electronic prescribing of the name, written inpatient medication orders, written outpatient prescriptions, verbal orders, and electronic orders are simulated, each consisting of a combination of marketed and unapproved drug products, including the proposed name.

d. Comments from Other Review Disciplines: DMEPA requests the Office of New Drugs (OND), Office of Generic Drugs (OGD), and/or Office of Pharmaceutical Quality (OPQ) for their comments or concerns with the proposed proprietary name, ask for any clinical issues that may impact the DMEPA review during the initial phase of the name review. Additionally, when applicable, at the same time DMEPA requests concurrence/non-

[i] Shah, M, Merchant, L, Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

concurrence with OPDP's decision on the name. The primary Safety Evaluator addresses any comments or concerns in the Safety Evaluator's assessment.

The OND/OGD Regulatory Division is contacted a second time following our analysis of the proposed proprietary name. At this point, DMEPA conveys their decision to accept or reject the name.

Additionally, other review disciplines opinions such as OPQ may be considered depending on the proposed proprietary name.

When provided, DMEPA considers external proprietary name studies conducted by or for the Applicant/Sponsor and incorporates the findings of these studies into the overall risk assessment.

The DMEPA primary Safety Evaluator assigned to evaluate the proposed proprietary name is responsible for considering the collective findings, and provides an overall risk assessment of the proposed proprietary name.

Table 4. Highly Similar Name Pair Checklist (i.e., combined Orthographic and Phonetic score is ≥ 70%).			
Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may render the names less likely to confusion, provided that the pair does not share a common strength or dose.			
Orthographic Checklist		Phonetic Checklist	
Y/N	Do the names begin with different first letters? *Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.*	Y/N	Do the names have different number of syllables?
Y/N	Are the lengths of the names dissimilar* when scripted? **FDA considers the length of names different if the names differ by two or more letters.*	Y/N	Do the names have different syllabic stresses?
Y/N	Considering variations in scripting of some letters (such as *z* and *f*), is there a different number or placement of upstroke/downstroke letters present in the names?	Y/N	Do the syllables have different phonologic processes, such vowel reduction, assimilation, or deletion?
Y/N	Is there different number or placement of cross-stroke or dotted letters present in the names?	Y/N	Across a range of dialects, are the names consistently pronounced differently?
Y/N	Do the infixes of the name appear dissimilar when scripted?		
Y/N	Do the suffixes of the names appear dissimilar when scripted?		

<table>
<tr><th colspan="3">Table 5: Moderately Similar Name Pair Checklist (i.e., combined score is ≥55% to ≤69%).</th></tr>
<tr><td>Step 1</td><td colspan="2">Review the DOSAGE AND ADMINISTRATION and HOW SUPPLIED/STORAGE AND HANDLING sections of the prescribing information (or for OTC drugs refer to the Drug Facts label) to determine if strengths and doses of the name pair overlap or are very similar. Different strengths and doses for products whose names are moderately similar may decrease the risk of confusion between the moderately similar name pairs. Name pairs that have overlapping or similar strengths or doses have a higher potential for confusion and should be evaluated further (see Step 2). Because the strength or dose could be used to express an order or prescription for a particular drug product, overlap in one or both of these components would be reason for further evaluation.
For single strength products, also consider circumstances where the strength may not be expressed.
For any i.e., drug products comprised of more than one active ingredient, consider whether the strength or dose may be expressed using only one of the components.
To determine whether the strengths or doses are similar to your proposed product, consider the following list of factors that may increase confusion:
• Alternative expressions of dose: 5 mL may be listed in the prescribing information, but the dose may be expressed in metric weight (e.g., 500 mg) or in non-metric units (e.g., 1 tsp, 1 tablet/capsule). Similarly, a strength or dose of 1000 mg may be expressed, in practice, as 1 g, or vice versa.
• Trailing or deleting zeros: 10 mg is similar in appearance to 100 mg which may potentiate confusion between a name pair with moderate similarity.
• Similar sounding doses: 15 mg is similar in sound to 50 mg</td></tr>
<tr><td>Step 2</td><td colspan="2">Answer the questions in the checklist below. Affirmative answers to some of these questions suggest that the pattern of orthographic or phonetic differences in the names may reduce the likelihood of confusion for moderately similar names with overlapping or similar strengths or doses.</td></tr>
<tr><td></td><td>Orthographic Checklist (Y/N to each question)
• Do the names begin with different first letters?
• Note that even when names begin with different first letters, certain letters may be confused with each other when scripted.
• Are the lengths of the names dissimilar* when scripted?
• *FDA considers the length of names different if the names differ by two or more letters.
• Considering variations in scripting of some letters (such as z and f), is there a different number or</td><td>Phonetic Checklist (Y/N to each question)
• Do the names have different number of syllables?
• Do the names have different syllabic stresses?
• Do the syllables have different phonologic processes, such vowel reduction, assimilation, or deletion?
• Across a range of dialects, are the names consistently pronounced differently?</td></tr>
</table>

Table 5: Moderately Similar Name Pair Checklist (i.e., combined score is **≥55%** to **≤69%).**		
	placement of upstroke/downstroke letters present in the names? • Is there different number or placement of cross-stroke or dotted letters present in the names? • Do the infixes of the name appear dissimilar when scripted? • Do the suffixes of the names appear dissimilar when scripted?	

Table 6. Low Similarity Name Pair Checklist (i.e., combined score is **≤54%).**
Names with low similarity are generally acceptable unless there are data to suggest that the name might be vulnerable to confusion (e.g., prescription simulation study suggests that the name is likely to be misinterpreted as a marketed product). In these instances, we would reassign a low similarity name to the moderate similarity category and review according to the moderately similar name pair checklist.

APPENDIX B. PRESCRIPTION SIMULATION SAMPLES AND RESULTS

Figure 1. Ebglyss Study (Conducted on 5/24/2024)

Handwritten Medication Order Prescription	Verbal Prescription
Medication Order:  Outpatient Prescription: 	Ebglyss 250 mg per 2 mL pen. Bring to clinic. Dispense one box.
CPOE Study Sample (displayed as sans-serif, 12-point, bold font)	
Ebglyss	

FDA Prescription Simulation Responses (Aggregate Report)					
Study Name: Ebglyss People Received Study: 197 People Responded: 65					
Total	18	15	12	20	65
INTERPRETATION	INPATIENT	OUTPATIENT	VOICE	CPOE	TOTAL
ABGLIS	0	0	1	0	1
ABGLISS	0	0	2	0	2
EBGLIS	0	0	1	0	1
EBGLISH	0	0	1	0	1
EBGLISS	0	0	3	0	3
EBGLIZ	0	0	1	0	1
EBGLYSA	1	0	0	0	1
EBGLYSBI	1	0	0	0	1
EBGLYSK	1	0	0	0	1
EBGLYSS	10	14	0	20	44

EBGLYSS 250 MG/2 ML PEN	0	1	0	0	1
EBGYLS	0	0	1	0	1
EBQLYSS	2	0	0	0	2
EBYLYSS	1	0	0	0	1
ELGLYSS	2	0	0	0	2
EVGLIS	0	0	1	0	1
MEBULIS	0	0	1	0	1

APPENDIX C. HIGHLY SIMILAR NAMES (e.g., combined POCA score is **≥70%)** – N/A

APPENDIX D. MODERATELY SIMILAR NAMES (e.g., combined POCA score is **≥55%** to **≤69%)** with no overlap or numerical similarity in Strength and/or Dose – N/A

APPENDIX E. MODERATELY SIMILAR NAMES (e.g., combined POCA score is **≥55%** to **≤69%)** with overlap or numerical similarity in Strength and/or Dose – N/A

APPENDIX F: LOW SIMILARITY NAMES (e.g., combined POCA score is **≤54%)**

No.	Name	POCA Score (%)
1.	Alymsys	46

APPENDIX G. Names not likely to be confused or not used in usual practice settings for the reasons described. – N/A

APPENDIX H. Names not likely to be confused due to absence of attributes that are known to cause name confusion[j]. – N/A

[j] Shah, M, Merchant, L, Chan, I, and Taylor, K. Characteristics That May Help in the Identification of Potentially Confusing Proprietary Drug Names. Therapeutic Innovation & Regulatory Science, September 2016

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MADHURI R PATEL
06/12/2024 11:22:19 AM

YEVGENIYA M KOGAN
06/12/2024 11:33:33 AM

IDALIA E RYCHLIK
06/12/2024 11:38:04 AM

SUFFIX REVIEW FOR NONPROPRIETARY NAME

Division of Medication Error Prevention and Analysis 1 (DMEPA 1)

Office of Medication Error Prevention and Risk Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	4/24/2023
Responsible OND Division:	Division of Dermatology and Dentistry (DDD)
Application Type and Number:	IND 119866
	BLA 761306
Product Name and Strength:	Egblyss (lebrikizumab-lbkz) injection,
	250 mg/2 mL (125 mg/mL)
Product Type:	Combination Product (Biologic-Device)
Applicant/Sponsor Name:	Eli Lilly and Company (Lilly)
FDA Received Date:	April 27, 2022 (IND)
	September 28, 2022 (BLA)
Nexus NPNS ID #:	2022-98 (IND)
	2022-135 (BLA)
DMAMES Biologics Suffix Specialist:	Carlos M Mena-Grillasca, BS Pharm
DMEPA 1 Director:	Mishale Mistry, PharmD, MPH

1 PURPOSE OF REVIEW

This review summarizes our evaluation of the four-letter suffixes proposed by Lilly for inclusion in the nonproprietary name and communicates our recommendation for the nonproprietary name for BLA 761306.

2 ASSESSMENT OF THE NONPROPRIETARY NAME

On September 28, 2022, Lilly submitted a list of 10 suffixes, in their order of preference, to be used in the nonproprietary name of their product[a]. Lilly also provided findings from an external study conducted by (b) (4)[a], evaluating the proposed four-letter suffixes in conjunction with the nonproprietary name, for our consideration. Table 1 presents a list of suffixes submitted by Lilly:

Table 1. Suffixes submitted by Lilly***

1.	lbkz
2.	(b) (4)
3.	
4.	
5.	
6.	
7.	
8.	
9.	
10.	

[a] Non-Proprietary Name Suffix Recommendation BLA 761306. (b) (4); 2022 Feb 07. Available from: \\CDSESUB1\EVSPROD\bla761306\0001\m1\us\ly3650150-nonproprietary-suffix-name-candidates-report.pdf

We reviewed Lilly's proposed suffixes in the order of preference listed by Lilly, along with the supporting data they submitted, using the principles described in the applicable guidance.[a]

2.1 lebrikizumab-lbkz

Lilly's first proposed suffix, -lbkz, is comprised of 4 distinct letters. We note that the proposed suffix may connote the core name 'lebrikizumab'. However, we do not object to suffixes that connote their own core name.

We determined that the proposed suffix -lbkz, is not too similar to any other products' suffix designation, does not look similar to the names of other currently marketed products, that the suffix is devoid of meaning, does not include any abbreviations that could be misinterpreted, and does not make any misrepresentations with respect to safety or efficacy of this product.

3 COMMUNICATION OF DMEPA 1 ANALYSIS

These findings were shared with OPDP. On April 12, 2023, OPDP did not identify any concerns that would render this proposed suffix unacceptable. DMEPA 1 also communicated our findings to the Division of Dermatology and Dentistry (DDD) on April 24, 2023.

4 CONCLUSION

We find Lilly's proposed suffix -lbkz acceptable and recommend the nonproprietary name be revised throughout the draft labels and labeling to lebrikizumab-lbkz. DMEPA 1 will communicate our findings to the Applicant via letter.

4.1 Recommendations for Eli Lilly and Company

We find the nonproprietary name, lebrikizumab-lbkz, conditionally acceptable for your proposed product. Should your 351(a) BLA be approved during this review cycle, lebrikizumab-lbkz will be the proper name designated in the license. You should revise your proposed labels and labeling accordingly and submit the revised labels and labeling to your BLA for our review. However, please be advised that if your application receives a complete response, the acceptability of your proposed

[a] Guidance for Industry: Nonproprietary Naming of Biological Products. 2017. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf

suffix will be re-evaluated when you respond to the deficiencies. If we find your suffix unacceptable upon our re-evaluation, we will inform you of our findings.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CARLOS M MENA-GRILLASCA
04/24/2023 05:31:18 PM

MISHALE P MISTRY
04/24/2023 09:31:18 PM

PROPRIETARY NAME MEMORANDUM

Division of Medication Error Prevention and Analysis 1 (DMEPA 1)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

***** This document contains proprietary information that cannot be released to the public*****

Date of This Review:	December 6, 2022
Application Type and Number:	BLA 761306
Product Name and Strength:	Ebglyss (lebrikizumab-xxxx)[a] injection, 250 mg/2 mL (125 mg/mL)
Product Type:	Combination Product (Drug-Device)
Rx or OTC:	Prescription (Rx)
Applicant/Sponsor Name:	Eli Lilly and Company (Eli Lilly)
PNR ID #:	2022-1044724776
DMEPA 1 Safety Evaluator:	Corwin D. Howard, PharmD, RPh
Acting DMEPA 1 Team Leader:	Madhuri R. Patel, PharmD
DMEPA 1 Associate Director for Nomenclature and Labeling:	Mishale Mistry, PharmD, MPH

[a] The non-proprietary name suffix for this product has not yet been determined; therefore, the placeholder lebrikizumab -xxxx is used throughout this review to refer to the non-proprietary name and suffix for this product.

1 INTRODUCTION

This memorandum is to reassess the proposed proprietary name, Ebglyss, which was found conditionally acceptable under IND 119866 on March 22, 2022.[b]

Thus, Eli Lilly submitted the name, Ebglyss, under BLA 761306 for review on September 28, 2022. We note [redacted] the frequency of maintenance dosing [redacted] 250 mg every 4 [redacted] weeks; there is also additional storage instructions to allow for storage at room temperature up to 30°C (86°F) for up to 7 days for BLA 761306. All other product characteristics remain the same.

2 METHODS AND DISCUSSION

2.1 MISBRANDING ASSESSMENT

The Office of Prescription Drug Promotion (OPDP) determined that Ebglyss would not misbrand the proposed product. The Division of Medication Error Prevention and Analysis 1 (DMEPA 1) concurred with the findings of OPDP's assessment for Ebglyss. The Division of Dermatology and Dentistry (DDD) concurred with the findings of OPDP's assessment for Ebglyss.

2.2 SAFETY ASSESSMENT

For re-assessment of the proposed proprietary name, we evaluated the previously identified names of concern considering any lessons learned from recent post-marketing experience, which may have altered our previous conclusion regarding the acceptability of the proposed proprietary name. We also evaluated previously identified names taking into account the [redacted] 1) frequency of maintenance dosing [redacted] 250 mg every 4 [redacted] weeks and 2) additional storage instructions to allow for storage at room temperature up to 30°C (86°F) for up to 7 days. Our evaluation has not altered our previous conclusion regarding the acceptability of the proposed proprietary name, Ebglyss.

Additionally, we searched the United States Adopted Name (USAN) stem list to determine if the proposed proprietary name contains any USAN stems as of the last USAN updates. The October 6, 2022 search of USAN stems did not find any USAN stems in the proposed proprietary name, Ebglyss.

2.3 COMMUNICATION OF DMEPA'S DETERMINATION

On December 6, 2022, we communicated our determination to the Division of Dermatology and Dentistry (DDD).

3 CONCLUSION

Our re-assessment did not identify any names that represent a potential source of drug name confusion. Therefore, we maintain that the proposed proprietary name, Ebglyss, is conditionally acceptable.

---

[b] Patel, M. Proprietary Name Review for Ebglyss (IND 119866). Silver Spring (MD): FDA, CDER, OSE, DMEPA 1 (US); 2022 MAR 22. PNR ID No. 2021-1044724212.

If you have any questions or need clarifications, please contact Tri Bui Nguyen, OSE project manager, at 240-402-3726.

3.1 COMMENTS TO ELI LILLY AND COMPANY

We have completed our review of the proposed proprietary name, Ebglyss, and have concluded that this name is conditionally acceptable.

If any of the proposed product characteristics as stated in your submission, received on September 28, 2022, are altered prior to approval of the marketing application, the name must be resubmitted for review.

4 REFERENCE

1. ***USAN Stems (https://www.ama-assn.org/about/united-states-adopted-names-approved-stems)***

   USAN Stems List contains all the recognized USAN stems.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CORWIN D HOWARD
12/06/2022 04:15:59 PM

MADHURI R PATEL
12/06/2022 07:21:09 PM

MISHALE P MISTRY
12/08/2022 09:50:17 AM